8-K filed October 6, 2021, 7:59 PM ET ticker PDSB CIK 0001472091

other material confidence high sentiment positive materiality 0.70

PDS Biotech terminates CFO, hires Hill; completes Phase 2 enrollment in head and neck cancer

PDS Biotechnology Corp

CFO Seth Van Voorhees terminated without cause Sept 30; CEO Bedu-Addo interim CFO, controller Trochimiuk interim PAO.
Matthew Hill appointed CFO effective Oct 18; salary $350k, 35% bonus, severance 12 mo base, inducement option for 202,800 shares.
Completed enrollment of first stage of CPI-naïve arm in VERSATILE-002 Phase 2 study for HPV16 head and neck cancer.
If >=4 of first 17 patients achieve objective response per RECIST 1.1, arm advances to second stage with total 54 patients; trial with Merck.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Matthew Hill

Chief Financial Officer

PDSB · PDS Biotechnology Corp

Effective: 2021-10-18
Filed: October 6, 2021, 7:59 PM ET

On October 4, 2021, the Company entered into an Executive Employment Agreement with Matthew Hill (the “ Employment Agreement ”), pursuant to which Mr. Hill will be appointed as the Company’s Chief Financial Officer, effective as of October 18, 2021 (the “ Effective Date ”).

Role change (interim)

Janetta Trochimiuk

interim principal accounting officer

PDSB · PDS Biotechnology Corp

Effective: 2021-09-30
Filed: October 6, 2021, 7:59 PM ET

Janetta Trochimiuk, the Company’s controller, will serve as the interim principal accounting officer

Role change (interim)

Frank Bedu-Addo

interim principal financial officer

PDSB · PDS Biotechnology Corp

Effective: 2021-09-30
Filed: October 6, 2021, 7:59 PM ET

Frank Bedu-Addo, the Company’s Chief Executive Officer, will serve as the Company’s interim principal financial officer

Departed

Seth Van Voorhees

Chief Financial Officer, principal financial officer and principal accounting officer

PDSB · PDS Biotechnology Corp

Effective: 2021-09-30
Successor: Matthew Hill
Filed: October 6, 2021, 7:59 PM ET

On September 30, 2021, PDS Biotechnology Corporation (the “ Company ”) delivered a notice of termination without cause to Seth Van Voorhees and removed him from his position as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew Hill was appointed as Chief Financial Officer at PDS Biotechnology Corp.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On October 4, 2021, the Company entered into an Executive Employment Agreement with Matthew Hill (the “ Employment Agreement ”), pursuant to which Mr. Hill will be appointed as the Company’s Chief Financial Officer, effective as of October 18, 2021 (the “ Effective Date ”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Janetta Trochimiuk changed role as interim principal accounting officer at PDS Biotechnology Corp.

Action: will serve as interim principal accounting officer
Role: interim principal accounting officer

Exact text from the filing

Janetta Trochimiuk, the Company’s controller, will serve as the interim principal accounting officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Frank Bedu-Addo changed role as interim principal financial officer at PDS Biotechnology Corp.

Action: will serve as interim principal financial officer
Role: interim principal financial officer

Exact text from the filing

Frank Bedu-Addo, the Company’s Chief Executive Officer, will serve as the Company’s interim principal financial officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Seth Van Voorhees departed as Chief Financial Officer, principal financial officer and principal accounting officer at PDS Biotechnology Corp.

Action: terminated without cause
Role: Chief Financial Officer, principal financial officer and principal accounting officer

Exact text from the filing

On September 30, 2021, PDS Biotechnology Corporation (the “ Company ”) delivered a notice of termination without cause to Seth Van Voorhees and removed him from his position as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer.

View on SEC.gov

PDS Biotechnology Corp filing history →

Source: SEC EDGAR

accession 0001140361-21-033839

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.